Meeting
2024 ASCO Genitourinary Cancers Symposium
Underutilization of androgen deprivation therapy (ADT) intensification for the treatment of men with metastatic hormone-sensitive prostate cancer (mHSPC): A systematic review of real-world database studies.
Authors
Amit D Raval
Bayer HealthCare Pharmaceuticals, Whippany, NJ
Amit D Raval , Stephanie Chen , Natasha Littleton , Niculae Constantinovici , Peter J. Goebell
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 66)
DOI
10.1200/JCO.2024.42.4_suppl.66
Abstract #
66
Poster Bd #
C1
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Real-world treatment patterns among patients diagnosed with metastatic castration-sensitive prostate cancer (mCSPC) in community oncology settings.
First Author: Daniel J. George
Poster
2024 ASCO Genitourinary Cancers Symposium
Real-world treatment patterns in patients with BRCA 1/2-positive (BRCA+) metastatic castration-resistant prostate cancer (mCRPC) initiating first-line (1L) therapy.
First Author: Mehmet Asim Bilen
Poster
2023 ASCO Genitourinary Cancers Symposium
Oncologists’ perspectives on metastatic hormone sensitive prostate cancer management.
First Author: Patrick Heckman
Poster
2023 ASCO Genitourinary Cancers Symposium
Utilization of metastatic hormone sensitive prostate cancer (mHSPC) treatment in a community oncology practice setting.
First Author: Terri Conner